ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q1 2023. The put-call ratio across all filers is 16.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,297 | -15.4% | 22,629 | +102.7% | 0.00% | – |
| Q2 2023 | $24,002 | +29.8% | 11,164 | +17.7% | 0.00% | – |
| Q1 2023 | $18,490 | -26.0% | 9,482 | +44.0% | 0.00% | – |
| Q4 2022 | $25,000 | 0.0% | 6,584 | +25.2% | 0.00% | – |
| Q3 2022 | $25,000 | -43.2% | 5,257 | -4.1% | 0.00% | – |
| Q2 2022 | $44,000 | -6.4% | 5,483 | +68.8% | 0.00% | – |
| Q1 2022 | $47,000 | +840.0% | 3,248 | +1270.5% | 0.00% | – |
| Q4 2021 | $5,000 | -44.4% | 237 | -30.7% | 0.00% | – |
| Q3 2021 | $9,000 | 0.0% | 342 | -12.8% | 0.00% | – |
| Q2 2021 | $9,000 | +80.0% | 392 | +116.6% | 0.00% | – |
| Q1 2021 | $5,000 | -16.7% | 181 | 0.0% | 0.00% | – |
| Q4 2020 | $6,000 | +20.0% | 181 | +9.7% | 0.00% | – |
| Q3 2020 | $5,000 | -37.5% | 165 | -7.8% | 0.00% | – |
| Q2 2020 | $8,000 | – | 179 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,680,149 | $24,681,000 | 9.63% |
| Grosvenor Holdings, L.L.C. | 1,517,212 | $22,288,000 | 4.35% |
| Redmile Group, LLC | 7,432,429 | $109,182,000 | 3.41% |
| MPM BioImpact LLC | 334,384 | $4,912,000 | 1.32% |
| Indie Asset Partners, LLC | 96,572 | $1,419,000 | 1.07% |
| Eventide Asset Management | 1,975,000 | $29,013,000 | 0.46% |
| HHLR ADVISORS, LTD. | 500,000 | $7,345,000 | 0.15% |
| Virtus ETF Advisers LLC | 19,193 | $282,000 | 0.13% |
| Walleye Capital LLC | 248,354 | $3,648,000 | 0.10% |
| Matrix Capital Management Company, LP | 400,000 | $5,876,000 | 0.07% |